Russian nuclear medicine has received a new tool for fighting cancer. The drug “Rakurs, 223Ra”, developed by FMBA specialists, has passed state registration and entered civil circulation. The first industrial batch has already been shipped to the country’s medical institutions.
Development and Production
The creation of the drug is the result of the work of the Federal Research and Clinical Center of Radiology and Oncology of the FMBA of Russia (Dimitrovgrad). This is one of the agency’s key sites specializing in full-cycle nuclear medicine.
The introduction of “Rakurs” is of strategic importance for the industry:
- Import Substitution: The drug ensures technological sovereignty in the niche of complex radiopharmaceuticals.
- Availability: Local production guarantees uninterrupted supplies of vital therapy for Russian patients, regardless of external factors.
Mechanism of Action and Indications
The innovative development is based on the radionuclide Radium-223 (223Ra). It is a therapeutic agent chemically similar to calcium, allowing it to accumulate in bone tissue, especially in zones of pathological growth.
| Target Patient Group | Clinical Effect |
|---|---|
| Patients with oncological diseases having metastatic bone lesions. |
|
“The introduction of the drug ‘Rakurs, 223Ra’ into medical practice is an important event for Russian medicine, opening up prospects for more effective therapy of oncological patients,” the FMBA official statement emphasizes.
Source: FMBA of Russia Press Service
